Investors Warned About Losses in Park Ha Biological Technology Class Action Lawsuit

Park Ha Biological Technology Co. Lawsuit Overview

In a recent development, Levi & Korsinsky, LLP has urged investors who experienced losses in Park Ha Biological Technology Co., Ltd., traded under NASDAQ symbol BYAH, to come forward. This invitation comes in light of a significant decline in the company’s share value and an escalating class action lawsuit. The firm's call to action is aimed at investors who acquired shares between December 27, 2024, and July 8, 2025, during which time the stock's trajectory took unprecedented turns.

Timeline of Events

The narrative begins with the company’s initial public offering (IPO), which was launched on December 27, 2024, at a price of $4.00 per share. The offering aimed to raise approximately $4.8 million, with 1,200,000 ordinary shares made available to investors. However, the share price surged dramatically in the months that followed, peaking at over $41.49 in July 2025, leading to a total market capitalization that exceeded $1 billion. This rise, however, was abruptly halted on July 8, 2025, when the stock plummeted to just $2.99 per share—a stunning 93% decrease in a single trading session. The sudden drop erased more than $1 billion in market value without any subsequent announcement or clarification from the company.

Allegations of Improper Trading Patterns

The complaint filed against Park Ha Biological Technology accuses the company of utilizing undisclosed promotional schemes that misled investors about the stock's true value. The timeline leading to this crash reveals a concerning trend. From December 30, 2024, onward, trading commenced with ordinary volumes suggesting steady interest. By June 2025, however, promotional activities allegedly designed to inflate share prices became evident, prompting questionable trading behavior.

On June 18, 2025, there were reported instructions in promotional chat groups encouraging buying activities around the stock. This led to shares closing at $34.99 on June 30, with no official corporate announcements or tangible operational achievements to justify such a valuation.

By the time the share price hit $41.49 on July 7, speculation intensified without any factual basis from the company. The silence from management at this critical juncture did not alleviate growing concerns among investors.

The Aftermath of the Collapse

The fallout from the July 8 crash constituted a pivotal moment in the company’s history, resulting in a dramatic loss for shareholders who had participated in the previous price escalations. The company's continued failure to file relevant disclosures or respond to the unusual trading activity exacerbated investor frustrations and drew scrutiny from legal analysts.

As the complaint notes, the company only acknowledged additional share issuances and the resignation of its sole independent director appointed after the IPO several months later, raising further questions about transparency and operational integrity.

Important Deadlines for Investors

Levi & Korsinsky is actively encouraging those eligible to come forward and potentially act as lead plaintiffs in the ongoing securities class action. To qualify, investors must meet specific criteria, including experiencing verified losses during the stated class period. The firm has set a deadline of September 28, 2026, for interested investors to submit their information or to inquire further about their eligibility.

This securities class action will be conducted under the jurisdiction of the United States District Court for the Southern District of New York, referencing the Private Securities Litigation Reform Act of 1995. Interested parties may contact Joseph E. Levi, Esq., directly via email or phone for additional guidance on submitting their claims.

Conclusion

As the situation develops, the call from Levi & Korsinsky serves as an essential warning to investors about the potential ramifications of the Park Ha Biological Technology saga. Vigilance and timely action could be pivotal for those impacted by the stock's sudden and dramatic shifts in value.